AKT/FOXM1/STMN1 signaling pathway activation by SMC1A promotes tumor growth in breast cancer
The Journal of Gene Medicine · 2024
DOI: 10.1002/jgm.3661 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Gene Medicine, 2024. Verfasst von Kaichun Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Shanghai Fourth People's Hospital, Tongji University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Signal Transduction, Chromosomal Proteins, Non-Histone, Cell Cycle Proteins. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Special Project of Clinical Research of Health Industry of Shanghai Municipal Health Commission, Scientific Research Project of Hongkou District Health Committee of Shanghai, Research Project of Shanghai Fourth People's Hospital.
Abstract (Originalsprache)
Background
Upregulation of SMC1A (Structural maintenance of chromosomes 1A) is linked with many types of cancer and its oncogenic function, which has been associated with crucial cellular mechanisms (cell division, cell cycle checkpoints regulation and DNA repair). Recent studies have shown that SMC1A was involved in breast cancer, although the exact mechanisms of SMC1A remain to be determined.
Methods
Using The Cancer Genome Atlas (TCGA) database, we examined SMC1A expression and its relation to other genes, including FOXM1 and STMN1. Short hairpin RNA was used to subsequently examine the biological roles of SMC1A in MDA‐MB‐231 and MDA‐MB‐468 cell lines. Bioinformatics were performed to identify the SMC1A‐related gene FOXM1.
Results
Here, we used the TCGA database to show that SMC1A is overexpressed in breast cancer. Later investigations showed SMC1A's role in breast cancer cell survival, apoptosis and invasion. Using bioinformatics and western blot assays, we confirmed that FOXM1 acted as the downstream of SMC1A, and SMC1A knockdown significantly downregulated the FOXM1 expression via the AKT signal pathway. Interestingly, the inhibition effects induced by SMC1A downregulation could be reversed by FOXM1 overexpression. In the clinic, SMC1A expression is favorably linked with FOXM1 expression in breast cancer tumor tissues.
Conclusions
Collectively, our results not only enhance our knowledge of SMC1A's molecular pathways in breast cancer, but also suggest a potential new therapeutic target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Shanghai Fourth People's Hospital, Tongji University School of Medicine, Shanghai, China.
- Department of Oncology, Tianyou Hospital, Tongji University School of Medicine, Shanghai, China.
- Department of Radiation Oncology, LongHua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Förderung
- Special Project of Clinical Research of Health Industry of Shanghai Municipal Health Commission
- Scientific Research Project of Hongkou District Health Committee of Shanghai
- Research Project of Shanghai Fourth People's Hospital
Zitieren
APA
Li, K., Dai, P., Li, J., Liu, L., Cheng, S., Fang, Q., & Wu, B. (2024). AKT/FOXM1/STMN1 signaling pathway activation by SMC1A promotes tumor growth in breast cancer. The Journal of Gene Medicine. https://doi.org/10.1002/jgm.3661
Vancouver
Li K, Dai P, Li J, Liu L, Cheng S, Fang Q, et al. AKT/FOXM1/STMN1 signaling pathway activation by SMC1A promotes tumor growth in breast cancer. The Journal of Gene Medicine. 2024. doi:10.1002/jgm.3661
BibTeX
@article{Li2024,
author = {Li, Kaichun and Dai, Ping and Li, Jian and Liu, Long and Cheng, Shiyu and Fang, Qingliang and Wu, Bingxiang},
title = {AKT/FOXM1/STMN1 signaling pathway activation by SMC1A promotes tumor growth in breast cancer},
journal = {The Journal of Gene Medicine},
year = {2024},
doi = {10.1002/jgm.3661}
}
EUVIMED